-
Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology
•
Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by DNE Capital, with participation from Yuanbio Venture Capital, its angel financing investor. The funds will be used to advance the industrialization of the fourth-generation…
-
Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities
•
China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan Lifeline’s (TYO: 7575) China unit Synexmed (Shenzhen) Co., Ltd for an undisclosed amount. This acquisition will enhance Enlight’s capabilities in the vascular intervention market. About Synexmed and the AcquisitionFounded in 2005, Synexmed specializes in supplying…
-
Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development
•
Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel financing round led exclusively by Dalton Venture. The proceeds will be utilized for the extraction of high-purity active collagen, the in-depth development of oral bone tissue-guided membrane adhesive and artificial cornea, and the establishment of…
-
Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round
•
Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised close to RMB 200 million (USD 29 million) in a Series A+ financing round. This investment will support the company’s ongoing research and development efforts in TCR therapies. Investor ParticipationThe financing round was led by…
-
Singde Yiyang Secures Series A Financing to Expand Wellness Services in China
•
Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions” of renminbi in a Series A financing round led by Genertec Investment. The company plans to implement a “1+X+N” layout, covering key regions and cities in China, with a target of over 10,000 beds. Company…
-
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
•
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE), according to the exchange. The offering will be sponsored by CICC. This move marks a significant step in Laekna’s growth strategy as it seeks to raise capital to further…
-
Immunophage Biotech Raises RMB 200 Million in Series B1 Financing for Clinical Trials
•
Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million) in the first phase of a Series B1 financing round, led by ZBJL Capital and supported by debt financing. The funds will be used to advance Phase II clinical studies for first-tier products and Phase…
-
Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally
•
The tech and biotech sectors are grappling with the implications of the collapse of US-based Silicon Valley Bank (SVB; Nasdaq: SIVB), which specialized in working with the tech and biopharma venture capital sectors. The bank was seized by the US government’s Federal Deposit Insurance Corporation (FDIC) on Friday, March 10,…
-
Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development
•
Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised USD 50 million in a Series B financing round. The round was led by INCE Capital and Qiming Venture Partners, with contributions from TF Capital, LongRiver Investments, 3SBio, Octagon Capital, and Lichen Private Equity Fund.…
-
Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development
•
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100 million in a Series B financing round. The round was led by Hankang Capital and included participation from Cybernaut, Yangzijiang Funds, Ennovation Ventures, and Matrix Partners China. The proceeds will be used to enhance the…
-
HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development
•
China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 14.35 million) in a pre-Series A financing round. The round was led by MING Bioventures, with participation from Shunwei Capital, China-Singapore Suzhou Industrial Park Private Equity Management Co., Ltd, and existing…
-
Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies
•
China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round. The round was led by Bainuo Capital, with participation from existing investor Hankang Capital. The proceeds will be used to support research and development and clinical studies for multiple…
-
Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development
•
Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with a contribution from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research…
-
HealiRNA Secures RMB 100 Million in Pre-Series A Funding for Nucleic Acid Drug Development
•
China-based nucleic acid drug specialist Suzhou HealiRNA has reportedly raised over RMB 100 million (USD 14.35 million) in a pre-Series A financing round. The round was led by MING Bioventures, with additional investments from Shunwei Capital, China-Singapore Suzhou Industrial Park Private Equity Management Co., Ltd, and existing investor Sequoia Capital…
-
Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Autoimmune Therapies
•
China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round, led by Bainuo Capital. Existing investor Hankang Capital also participated in the round. The proceeds will be used to support research and development and clinical studies for multiple autoimmune…
-
Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development
•
Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with additional funding from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research…
-
AmVision Biotech Secures Nearly $14.34M in Series A+ for Ophthalmology Innovations
•
AmVision Biotech, a leading ophthalmology device platform company based in Guangzhou, has reportedly secured close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The round was led by Green Pine Capital Partners, with participation from ZDVC and existing investor HM Capital, among others. This significant…
-
Chongqing Evaheart Secures Near $100M in Series A for Heart Failure Platform
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in a Series A financing round. The round was led by Sinovac, with significant contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The funds raised will be directed towards the development…
-
AmVision Biotech Secures RMB 100 Million in Series A+ Financing for Ophthalmology Innovation
•
AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to RMB 100 million (USD 14.34 million) in a Series A+ financing round. The funding was led by Green Pine Capital Partners, with contributions from ZDVC and existing investor HM Capital, among others. This investment will…
-
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
•
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in a Series A financing round led by Sinovac, with contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The proceeds will be used to develop and construct a comprehensive heart failure…
